1/3/2024 0 Comments Keynote 522 2022![]() The prognostic value of SET2,3 remained significant at 10 years with nearly 78 percent of SET2,3 high patients being disease-free versus 58 percent of SET2,3 low patients. Otto Metzger of Dana-Farber Cancer Institute reported that 86 percent of patients with high SET2,3 measures were disease-free at five years versus 69 percent of patients with low SET2,3 measures. Presenting results from the phase 3 CALGB 9741 study, Dr. Fraser Symmans is a gene-based assay that measures the level of estrogen-induced gene activation in breast cancer cells. The SET2,3 test developed with BCRF support by Dr. New test identifies patients with estrogen receptor (ER)–positive breast cancer most likely to benefit from chemotherapy Because HER2-positive breast cancer is a diverse set of diseases, these findings could help doctors select the right drugs for patients. The five categories were based on gene signatures-groupings of gene expression profiles related to specific cell functions. The I-SPY2 study, supported in part by BCRF, is a uniquely designed clinical trial testing novel agents in the neoadjuvant (pre-surgical) setting to identify drugs that are most likely to show a significant benefit in phase 3 studies of early-stage breast cancer.Īt ASCO, I-SPY2 investigators presented results from one study that found five new molecular subtypes of HER2-positive breast cancer-the presence of which predicted the likelihood of pathologic complete response to a variety of agents including immunotherapies. Tumor molecular profiling for predicting treatment response in early-stage HER2-positive breast cancer Pembrolizumab was the first immunotherapy drug approved for early-stage breast cancer and these findings further confirm and extend its benefit to some TNBC patients. All patients benefitted from pembrolizumab including patients with residual tumor at the time of surgery who continued to receive pembrolizumab after surgery. Those with residual tumor at the time of surgery continued to receive the combination or chemotherapy alone. It demonstrated that patients with stage 2/3 TNBC receiving the immunotherapy drug pembrolizumab (KETRUDA®) plus chemotherapy had a superior response compared to those receiving chemotherapy alone prior to surgery. Lajos Pusztai presented an exploratory analysis from the KEYNOTE 522 ( NCT03036488) study. Triple-negative breast cancer (TNBC) remains a challenging disease to treat, but a type of immunotherapy called checkpoint blockade has emerged as a promising treatment for some patients. Immunotherapy improves response in patients with early-stage TNBC Study findings revealed a very low rate of five-year local recurrence at 2.3 percent, suggesting that certain patients with low-risk breast cancer may be able to avoid adjuvant radiation. ![]() ![]() The phase 3 LUMINA study ( NCT01791829) evaluated recurrence risk in women with luminal A low-grade, early-stage breast cancer who have undergone breast-conserving surgery and were treated with adjuvant endocrine therapy alone, without radiation. Some women with low-risk, early-stage breast cancer may forego radiation therapy after surgery. Here we highlight some of these noteworthy presentations on early-stage breast cancer. While it generally has a good prognosis, researchers are steadily working to improve outcomes and match the right treatments to patients for the most benefit. ![]() This year’s meeting included notable developments in early-stage breast cancer, that which has not spread beyond the breast or nearby lymph nodes and can be classified as stage 0 to 3A. At the American Society of Clinical Oncology’s (ASCO) annual meeting, BCRF investigators and other leading breast cancer researchers presented recent findings from the field-highlighting a banner year for advancements to improve diagnosis, treatment, and prognoses for patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |